OPKO Health, Inc. Segment Reporting Other Item Amount
OPKO Health, Inc. (OPK) reported Segment Reporting Other Item Amount of -$18.07 million for the 3-month period ending 2026-06-30, per its 10-Q/A filed 2026-08-28.
Financial Statements › Notes › Segment Reporting
us-gaap:SegmentReportingOtherItemAmount · last filed 2026-08-28
- OPKO Health, Inc. segment reporting other item amount for the quarter ending 2026-06-30 was -$18.07M.
- OPKO Health, Inc. segment reporting other item amount for the quarter ending 2026-03-31 was $18.97M, a 4.51% decline year-over-year.
- OPKO Health, Inc. segment reporting other item amount for the quarter ending 2025-12-31 was $0.00.
- OPKO Health, Inc. segment reporting other item amount for the quarter ending 2025-09-30 was -$101.58M.
- OPKO Health, Inc. segment reporting other item amount for fiscal 2025 was -$101.58M.
- OPKO Health, Inc. segment reporting other item amount for fiscal 2024 was -$121.49M.
- OPKO Health, Inc. segment reporting other item amount for fiscal 2023 was -$1.04M.
- OPKO Health, Inc. segment reporting other item amount for fiscal 2022 was -$19.87M.
| Period end | Segment Reporting Other Item Amount 3 month | Segment Reporting Other Item Amount 6 month | Segment Reporting Other Item Amount 9 month | Segment Reporting Other Item Amount 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$18.07M 10-Q/A · filed 2026-08-28 | -$18.07M 10-Q/A · filed 2026-08-28 | $896.00K derived: sum of 3 quarters · filed 2026-08-28 | -$100.68M derived: sum of 4 quarters · filed 2026-08-28 |
| 2026-03-31 | $18.97M 10-Q/A · filed 2026-08-28 | $18.97M derived: sum of 2 quarters · filed 2026-08-28 | -$82.61M derived: sum of 3 quarters · filed 2026-08-28 | -$82.61M derived: sum of 4 quarters · filed 2026-08-28 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$101.58M derived: sum of 2 quarters · filed 2026-02-26 | -$101.58M derived: sum of 3 quarters · filed 2026-08-28 | -$101.58M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$101.58M 10-Q · filed 2025-10-29 | -$101.58M derived: sum of 2 quarters · filed 2026-08-28 | -$101.58M 10-Q · filed 2025-10-29 | -$81.72M derived: sum of 4 quarters · filed 2026-08-28 |
| 2025-06-30 | $0.00 10-Q/A · filed 2026-08-28 | $0.00 10-Q/A · filed 2026-08-28 | $19.86M derived: sum of 3 quarters · filed 2026-08-28 | -$101.63M derived: sum of 4 quarters · filed 2026-08-28 |
| 2025-03-31 | $19.86M 10-Q/A · filed 2026-08-28 | $19.86M derived: sum of 2 quarters · filed 2026-08-28 | -$101.63M derived: sum of 3 quarters · filed 2026-08-28 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$121.49M derived: sum of 2 quarters · filed 2026-02-26 | -$121.49M 10-K · filed 2026-02-26 | |
| 2024-09-30 | -$121.49M 10-Q · filed 2025-10-29 | -$121.49M 10-Q · filed 2025-10-29 | ||
| 2023-12-31 | -$1.04M 10-K · filed 2026-02-26 | |||
| 2022-12-31 | -$19.87M 10-K · filed 2025-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |